Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 152

1.

[Hypoparathyroidism - un underestimated problem?]

Petersenn S, Bojunga J, Brabant G, Etzrodt-Walter G, Finke R, Scharla S, Stamm B, Weber MM, Wicke C, Siggelkow H.

MMW Fortschr Med. 2019 Dec;161(Suppl 7):12-20. doi: 10.1007/s15006-019-1174-4. Review. German.

PMID:
31828671
2.

Management of Aggressive Pituitary Tumors - A 2019 Update.

Petersenn S.

Horm Metab Res. 2019 Dec;51(12):755-764. doi: 10.1055/a-1060-1883. Epub 2019 Dec 11.

PMID:
31826270
3.

Use of late-night salivary cortisol to monitor response to medical treatment in Cushing's disease.

Newell-Price J, Pivonello R, Tabarin A, Fleseriu M, Witek P, Gadelha MR, Petersenn S, Tauchmanova L, Ravichandran S, Gupta P, Lacroix A, Biller B.

Eur J Endocrinol. 2019 Dec 1. pii: EJE-19-0695.R1. doi: 10.1530/EJE-19-0695. [Epub ahead of print]

PMID:
31804965
4.

Efficacy of temozolomide therapy in patients with aggressive pituitary adenomas and carcinomas - a German survey.

Elbelt U, Schlaffer SM, Buchfelder M, Knappe UJ, Vila G, Micko A, Deutschbein T, Unger N, Lammert A, Topuzoglu-Müller T, Bojunga J, Droste M, Johanssen S, Kolenda H, Ritzel K, Buslei R, Strasburger CJ, Petersenn S, Honegger J.

J Clin Endocrinol Metab. 2019 Nov 20. pii: dgz211. doi: 10.1210/clinem/dgz211. [Epub ahead of print]

PMID:
31746334
5.

A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update.

Giustina A, Barkan A, Beckers A, Biermasz N, Biller BMK, Boguszewski C, Bolanowski M, Bonert V, Bronstein MD, Casanueva FF, Clemmons D, Colao A, Ferone D, Fleseriu M, Frara S, Gadelha MR, Ghigo E, Gurnell M, Heaney AP, Ho K, Ioachimescu A, Katznelson L, Kelestimur F, Kopchick J, Krsek M, Lamberts S, Losa M, Luger A, Maffei P, Marazuela M, Mazziotti G, Mercado M, Mortini P, Neggers S, Pereira AM, Petersenn S, Puig-Domingo M, Salvatori R, Shimon I, Strasburger C, Tsagarakis S, van der Lely AJ, Wass J, Zatelli MC, Melmed S.

J Clin Endocrinol Metab. 2019 Oct 13. pii: dgz096. doi: 10.1210/clinem/dgz096. [Epub ahead of print]

PMID:
31606735
6.

Clinical situation, therapy, and follow up of adult craniopharyngioma - report from the German craniopharyngioma registry.

Mende KC, Kellner T, Petersenn S, Honegger J, Evangelista-Zamora R, Droste M, Stalla G, Deutschbein T, Wang Y, Moskopp D, Knappe U, Schilbach K, Flitsch J; “pituitary working group” of the German Society of Endocrinology (DGE).

J Clin Endocrinol Metab. 2019 Oct 7. pii: dgz043. doi: 10.1210/clinem/dgz043. [Epub ahead of print]

PMID:
31589293
7.

Long-term efficacy and safety of once-monthly pasireotide in Cushing's disease: A Phase III extension study.

Fleseriu M, Petersenn S, Biller BMK, Kadioglu P, De Block C, T'Sjoen G, Vantyghem MC, Tauchmanova L, Wojna J, Roughton M, Lacroix A, Newell-Price J.

Clin Endocrinol (Oxf). 2019 Dec;91(6):776-785. doi: 10.1111/cen.14081. Epub 2019 Oct 1.

8.

Staging and managing patients with acromegaly in clinical practice: baseline data from the SAGIT® validation study.

Giustina A, Bronstein MD, Chanson P, Petersenn S, Casanueva FF, Sert C, Houchard A, Melmed S.

Pituitary. 2019 Oct;22(5):476-487. doi: 10.1007/s11102-019-00977-5.

9.

Pituitary Disease in Pregnancy: Special Aspects of Diagnosis and Treatment?

Petersenn S, Christ-Crain M, Droste M, Finke R, Flitsch J, Kreitschmann-Andermahr I, Luger A, Schopohl J, Stalla G.

Geburtshilfe Frauenheilkd. 2019 Apr;79(4):365-374. doi: 10.1055/a-0794-7587. Epub 2019 Mar 6.

10.

MRI T2 signal intensity and tumor response in patients with GH-secreting pituitary macroadenoma: PRIMARYS post-hoc analysis.

Bonneville F, Rivière LD, Petersenn S, Bevan J, Houchard A, Sert C, Caron PJ; PRIMARYS Study group.

Eur J Endocrinol. 2018 Dec 1. pii: EJE-18-0254.R2. doi: 10.1530/EJE-18-0254. [Epub ahead of print]

PMID:
30540560
11.

Neuroendocrine neoplasms - think about it and choose the most appropriate diagnostic and therapeutic steps.

Koch CA, Petersenn S.

Rev Endocr Metab Disord. 2018 Jun;19(2):107-109. doi: 10.1007/s11154-018-9472-1. No abstract available.

PMID:
30357544
12.

Black swans - neuroendocrine tumors of rare locations.

Koch CA, Petersenn S.

Rev Endocr Metab Disord. 2018 Jun;19(2):111-121. doi: 10.1007/s11154-018-9473-0.

PMID:
30341705
13.

Aggressive pituitary tumours and carcinomas: two sides of the same coin?

Trouillas J, Burman P, McCormack A, Petersenn S, Popovic V, Dekkers O, Raverot G.

Eur J Endocrinol. 2018 Jun;178(6):C7-C9. doi: 10.1530/EJE-18-0250. Epub 2018 Mar 27. Review.

PMID:
29588294
14.

Secondary adrenal insufficiency in pregnancy: any differences?

Petersenn S.

Minerva Endocrinol. 2018 Dec;43(4):446-450. doi: 10.23736/S0391-1977.18.02840-7. Epub 2018 Mar 15. Review.

PMID:
29546743
15.

Pituitary disease management during pregnancy: an overview.

Petersenn S.

Minerva Endocrinol. 2018 Dec;43(4):420-422. doi: 10.23736/S0391-1977.18.02835-3. Epub 2018 Mar 15. No abstract available.

16.

Neuroendocrine neoplasms - still a challenge despite major advances in clinical care with the development of specialized guidelines.

Petersenn S, Koch CA.

Rev Endocr Metab Disord. 2017 Dec;18(4):373-378. doi: 10.1007/s11154-018-9442-7. No abstract available.

PMID:
29480376
17.

Editorial : Neuroendocrine neoplasms.

Koch CA, Petersenn S.

Rev Endocr Metab Disord. 2017 Dec;18(4):379-380. doi: 10.1007/s11154-018-9441-8. No abstract available.

PMID:
29417306
18.

Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016.

McCormack A, Dekkers OM, Petersenn S, Popovic V, Trouillas J, Raverot G, Burman P; ESE survey collaborators.

Eur J Endocrinol. 2018 Mar;178(3):265-276. doi: 10.1530/EJE-17-0933. Epub 2018 Jan 12.

PMID:
29330228
19.

Targeting CXCR4 (CXC Chemokine Receptor Type 4) for Molecular Imaging of Aldosterone-Producing Adenoma.

Heinze B, Fuss CT, Mulatero P, Beuschlein F, Reincke M, Mustafa M, Schirbel A, Deutschbein T, Williams TA, Rhayem Y, Quinkler M, Rayes N, Monticone S, Wild V, Gomez-Sanchez CE, Reis AC, Petersenn S, Wester HJ, Kropf S, Fassnacht M, Lang K, Herrmann K, Buck AK, Bluemel C, Hahner S.

Hypertension. 2018 Feb;71(2):317-325. doi: 10.1161/HYPERTENSIONAHA.117.09975. Epub 2017 Dec 26.

20.

European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas.

Raverot G, Burman P, McCormack A, Heaney A, Petersenn S, Popovic V, Trouillas J, Dekkers OM; European Society of Endocrinology.

Eur J Endocrinol. 2018 Jan;178(1):G1-G24. doi: 10.1530/EJE-17-0796. Epub 2017 Oct 18. Review.

PMID:
29046323
21.

Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial.

Lacroix A, Gu F, Gallardo W, Pivonello R, Yu Y, Witek P, Boscaro M, Salvatori R, Yamada M, Tauchmanova L, Roughton M, Ravichandran S, Petersenn S, Biller BMK, Newell-Price J; Pasireotide G2304 Study Group.

Lancet Diabetes Endocrinol. 2018 Jan;6(1):17-26. doi: 10.1016/S2213-8587(17)30326-1. Epub 2017 Oct 12. Erratum in: Lancet Diabetes Endocrinol. 2018 Jan;6(1):e1.

PMID:
29032078
22.

[Diagnostics and treatment of acromegaly : Necessity for targeted monitoring of comorbidities].

Petersenn S, Christ-Crain M, Droste M, Finke R, Flitsch J, Kreitschmann-Andermahr I, Luger A, Schopohl J, Stalla G.

Internist (Berl). 2017 Nov;58(11):1171-1182. doi: 10.1007/s00108-017-0331-z. Review. German.

PMID:
29027568
23.

Long-term treatment of Cushing's disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial.

Petersenn S, Salgado LR, Schopohl J, Portocarrero-Ortiz L, Arnaldi G, Lacroix A, Scaroni C, Ravichandran S, Kandra A, Biller BMK.

Endocrine. 2017 Jul;57(1):156-165. doi: 10.1007/s12020-017-1316-3. Epub 2017 Jun 9.

24.

Clinical Characterization of the Pheochromocytoma and Paraganglioma Susceptibility Genes SDHA, TMEM127, MAX, and SDHAF2 for Gene-Informed Prevention.

Bausch B, Schiavi F, Ni Y, Welander J, Patocs A, Ngeow J, Wellner U, Malinoc A, Taschin E, Barbon G, Lanza V, Söderkvist P, Stenman A, Larsson C, Svahn F, Chen JL, Marquard J, Fraenkel M, Walter MA, Peczkowska M, Prejbisz A, Jarzab B, Hasse-Lazar K, Petersenn S, Moeller LC, Meyer A, Reisch N, Trupka A, Brase C, Galiano M, Preuss SF, Kwok P, Lendvai N, Berisha G, Makay Ö, Boedeker CC, Weryha G, Racz K, Januszewicz A, Walz MK, Gimm O, Opocher G, Eng C, Neumann HPH; European-American-Asian Pheochromocytoma-Paraganglioma Registry Study Group.

JAMA Oncol. 2017 Sep 1;3(9):1204-1212. doi: 10.1001/jamaoncol.2017.0223.

25.

National German Audit of Diagnosis, Treatment, and Teaching in Secondary Adrenal Insufficiency.

Petersenn S, Honegger J, Quinkler M.

Horm Metab Res. 2017 Aug;49(8):580-588. doi: 10.1055/s-0043-105077. Epub 2017 Mar 28.

PMID:
28351092
26.

Anthropometric factors have significant influence on the outcome of the GHRH-arginine test: establishment of normative data for an automated immunoassay specifically measuring 22 kDa human growth hormone.

Deutschbein T, Bidlingmaier M, Schopohl J, Strasburger CJ, Petersenn S.

Eur J Endocrinol. 2017 Mar;176(3):273-281. doi: 10.1530/EJE-16-0668. Epub 2016 Dec 8.

PMID:
27932410
27.

Glucose and lipid levels with lanreotide autogel 120 mg in treatment-naïve patients with acromegaly: data from the PRIMARYS study.

Caron PJ, Petersenn S, Houchard A, Sert C, Bevan JS; PRIMARYS Study Group.

Clin Endocrinol (Oxf). 2017 Apr;86(4):541-551. doi: 10.1111/cen.13285. Epub 2016 Dec 27.

PMID:
27874199
28.

Late-night salivary cortisol may be valuable for assessing treatment response in patients with Cushing's disease: 12-month, Phase III pasireotide study.

Findling JW, Fleseriu M, Newell-Price J, Petersenn S, Pivonello R, Kandra A, Pedroncelli AM, Biller BM.

Endocrine. 2016 Nov;54(2):516-523. Epub 2016 May 21.

29.

Health-related Quality of Life in Patients After Treatment of Cushing's Disease.

Nader S, Burkhardt T, Vettorazzi E, Milian M, Aberle J, Petersenn S, Flitsch J.

Exp Clin Endocrinol Diabetes. 2016 Mar;124(3):187-91. doi: 10.1055/s-0035-1569340. Epub 2016 Mar 23.

PMID:
27008635
30.

Erratum: Histological criteria for atypical pituitary adenomas--data from the German pituitary adenoma registry suggests modifications.

Miermeister CP, Petersenn S, Buchfelder M, Fahlbusch R, Lüdecke DK, Hölsken A, Bergmann M, Knappe UJ, Hans VH, Flitsch J, Saeger W, Buslei R.

Acta Neuropathol Commun. 2016 Feb 29;4:21. doi: 10.1186/s40478-016-0290-y.

31.

Emerging Histopathological and Genetic Parameters of Pituitary Adenomas: Clinical Impact and Recommendation for Future WHO Classification.

Saeger W, Petersenn S, Schöfl C, Knappe UJ, Theodoropoulou M, Buslei R, Honegger J.

Endocr Pathol. 2016 Jun;27(2):115-22. doi: 10.1007/s12022-016-9419-6. Review.

PMID:
26874696
32.

Clinical Impact of the Current WHO Classification of Pituitary Adenomas.

Saeger W, Honegger J, Theodoropoulou M, Knappe UJ, Schöfl C, Petersenn S, Buslei R.

Endocr Pathol. 2016 Jun;27(2):104-14. doi: 10.1007/s12022-016-9418-7. Review.

PMID:
26860936
33.

Effects of lanreotide Autogel primary therapy on symptoms and quality-of-life in acromegaly: data from the PRIMARYS study.

Caron PJ, Bevan JS, Petersenn S, Houchard A, Sert C, Webb SM; PRIMARYS Investigators Group.

Pituitary. 2016 Apr;19(2):149-57. doi: 10.1007/s11102-015-0693-y.

34.

How to manage pasireotide, when using as medical treatment for Cushing's disease.

Petersenn S.

Endocrine. 2015 Dec;50(3):526-8. doi: 10.1007/s12020-015-0754-z. Epub 2015 Sep 29. No abstract available.

PMID:
26419848
35.

SAGIT®: clinician-reported outcome instrument for managing acromegaly in clinical practice--development and results from a pilot study.

Giustina A, Bevan JS, Bronstein MD, Casanueva FF, Chanson P, Petersenn S, Thanh XM, Sert C, Houchard A, Guillemin I, Melmed S; SAGIT Investigator Group.

Pituitary. 2016 Feb;19(1):39-49. doi: 10.1007/s11102-015-0681-2.

36.

Histological criteria for atypical pituitary adenomas - data from the German pituitary adenoma registry suggests modifications.

Miermeister CP, Petersenn S, Buchfelder M, Fahlbusch R, Lüdecke DK, Hölsken A, Bergmann M, Knappe HU, Hans VH, Flitsch J, Saeger W, Buslei R.

Acta Neuropathol Commun. 2015 Aug 19;3:50. doi: 10.1186/s40478-015-0229-8. Erratum in: Acta Neuropathol Commun. 2016;4(1):21.

37.

Diagnosis of Primary Hypophysitis in Germany.

Honegger J, Schlaffer S, Menzel C, Droste M, Werner S, Elbelt U, Strasburger C, Störmann S, Küppers A, Streetz-van der Werf C, Deutschbein T, Stieg M, Rotermund R, Milian M, Petersenn S; Pituitary Working Group of the German Society of Endocrinology.

J Clin Endocrinol Metab. 2015 Oct;100(10):3841-9. doi: 10.1210/jc.2015-2152. Epub 2015 Aug 11.

PMID:
26262437
38.

Treatment of Primary Hypophysitis in Germany.

Honegger J, Buchfelder M, Schlaffer S, Droste M, Werner S, Strasburger C, Störmann S, Schopohl J, Kacheva S, Deutschbein T, Stalla G, Flitsch J, Milian M, Petersenn S, Elbelt U; Pituitary Working Group of the German Society of Endocrinology.

J Clin Endocrinol Metab. 2015 Sep;100(9):3460-9. doi: 10.1210/jc.2015-2146. Epub 2015 Jun 19.

PMID:
26091204
39.

Cushing disease: where do we stand, where are we heading?

Fleseriu M, Petersenn S.

Pituitary. 2015 Apr;18(2):179-80. doi: 10.1007/s11102-015-0647-4. No abstract available.

PMID:
25759331
40.

Pituitary-directed medical therapy in Cushing's disease.

Petersenn S, Fleseriu M.

Pituitary. 2015 Apr;18(2):238-44. doi: 10.1007/s11102-015-0639-4. Review.

PMID:
25627118
41.

Therapy of endocrine disease: outcomes in patients with Cushing's disease undergoing transsphenoidal surgery: systematic review assessing criteria used to define remission and recurrence.

Petersenn S, Beckers A, Ferone D, van der Lely A, Bollerslev J, Boscaro M, Brue T, Bruzzi P, Casanueva FF, Chanson P, Colao A, Reincke M, Stalla G, Tsagarakis S.

Eur J Endocrinol. 2015 Jun;172(6):R227-39. doi: 10.1530/EJE-14-0883. Epub 2015 Jan 19. Review.

PMID:
25599709
42.

Computed tomography criteria for discrimination of adrenal adenomas and adrenocortical carcinomas: analysis of the German ACC registry.

Petersenn S, Richter PA, Broemel T, Ritter CO, Deutschbein T, Beil FU, Allolio B, Fassnacht M; German ACC Study Group.

Eur J Endocrinol. 2015 Apr;172(4):415-22. doi: 10.1530/EJE-14-0916. Epub 2015 Jan 19.

PMID:
25599706
43.

Total Testosterone and Calculated Estimates for Free and Bioavailable Testosterone: Influence of Age and Body Mass Index and Establishment of Sex-Specific Reference Ranges.

Deutschbein T, Mann K, Petersenn S.

Horm Metab Res. 2015 Oct;47(11):846-54. doi: 10.1055/s-0034-1395569. Epub 2015 Jan 7.

PMID:
25565093
44.

Medical therapy for Cushing's disease: adrenal steroidogenesis inhibitors and glucocorticoid receptor blockers.

Fleseriu M, Petersenn S.

Pituitary. 2015 Apr;18(2):245-52. doi: 10.1007/s11102-014-0627-0. Review.

PMID:
25560275
45.

Sagit©: A Novel Clinician-Reported Outcome for Managing Acromegaly in Clinical Practice.

Giustina A, Bevan J, Bronstein M, Casanueva F, Chanson P, Petersenn S, Truong TX, Massien C, Dias-Barbosa C, Guillemin I, Arnould B, Melmed S.

Value Health. 2014 Nov;17(7):A355. doi: 10.1016/j.jval.2014.08.754. Epub 2014 Oct 26. No abstract available.

46.

Treatment of malignant phaeochromocytoma with a combination of cyclophosphamide, vincristine and dacarbazine: own experience and overview of the contemporary literature.

Deutschbein T, Fassnacht M, Weismann D, Reincke M, Mann K, Petersenn S.

Clin Endocrinol (Oxf). 2015 Jan;82(1):84-90. doi: 10.1111/cen.12590. Epub 2014 Oct 24.

PMID:
25143180
47.

Expression analysis of GADD45γ, MEG3, and p8 in pituitary adenomas.

Binse I, Ueberberg B, Sandalcioglu IE, Flitsch J, Luedecke DK, Mann K, Petersenn S.

Horm Metab Res. 2014 Aug;46(9):644-50. doi: 10.1055/s-0034-1383566. Epub 2014 Aug 15.

PMID:
25126861
48.

Pharmacokinetics, pharmacodynamics, and safety of pasireotide LAR in patients with acromegaly: a randomized, multicenter, open-label, phase I study.

Petersenn S, Bollerslev J, Arafat AM, Schopohl J, Serri O, Katznelson L, Lasher J, Hughes G, Hu K, Shen G, Reséndiz KH, Giannone V, Beckers A.

J Clin Pharmacol. 2014 Nov;54(11):1308-17. doi: 10.1002/jcph.326. Epub 2014 May 24.

PMID:
24800725
49.

Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase III study.

Pivonello R, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Trovato A, Hughes G, Salgado LR, Lacroix A, Schopohl J, Biller BM; Pasireotide B2305 Study Group.

Clin Endocrinol (Oxf). 2014 Sep;81(3):408-17. doi: 10.1111/cen.12431. Epub 2014 Mar 27.

PMID:
24533697
50.

Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial.

Caron PJ, Bevan JS, Petersenn S, Flanagan D, Tabarin A, Prévost G, Maisonobe P, Clermont A; PRIMARYS Investigators.

J Clin Endocrinol Metab. 2014 Apr;99(4):1282-90. doi: 10.1210/jc.2013-3318. Epub 2013 Jan 1.

Supplemental Content

Loading ...
Support Center